Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease

NCT04325620 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

208

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-erosive Gastroesphageal Reflux Disease

Interventions

DRUG: HIP1601
DRUG: HGP1805

Sponsor

Hanmi Pharmaceutical Company Limited